ViewRay® Newsroom

Compelling Early Pancreatic Cancer Data with ViewRay’s MRIdian System Presented at ESTRO 36

Presentations Also Highlighted Speed and Benefit of On-Table Adaptive Therapy in Routine Clinical Use

May 15, 2017

CLEVELAND, May 15, 2017 — ViewRay, Inc. (Nasdaq: VRAY) announced today highlights from ESTRO 36, the annual meeting of the European Society for Radiotherapy and Oncology, which featured broad clinical experience with the company’s MRIdian System, including compelling early data on its use in pancreatic cancer.

Pancreatic Cancer
A presentation by Sasa Mutic, Ph.D., from Washington University School of Medicine in St. Louis, highlighted early retrospective multi-institutional data on pancreatic cancer treatments with MRIdian at University of California, Los Angeles (UCLA) Health System; University of Wisconsin Carbone Cancer Center; VU University Medical Center; and Washington University School of Medicine. The study compared SBRT treatments with and without on-table adaptive dose reshaping and found that delivering a higher biological dose, enabled by MRI-guided on-table adaptive radiotherapy, may lead to improved survival in locally advanced pancreatic cancer.

A second clinical presentation on pancreatic cancer treatment with MRIdian was given by Anna Bruynzeel, M.D., Ph.D., from VU University Medical Center, focusing on their single-institutional experience. Early results illustrated MRIdian’s ability to deliver high doses with low toxicity, despite the proximity of the duodenum, through the use of daily plan adaptation and real-time tracking.

Following the promising data presented at ESTRO, ViewRay plans to support a multi-institutional single-arm prospective clinical trial in unresectable pancreatic cancer to demonstrate the benefits of MRIdian’s daily on-table adaptive SBRT and real-time tissue tracking capabilities, with a focus on toxicity, local control and overall survival outcomes.

Clinical Benefits of On-Table Adaptive Treatment
In a talk in ViewRay’s booth, Frank Lagerwaard, M.D. Ph.D. of VU University Medical Center highlighted the excellent image quality of MRIdian and reported that on-table adaptation takes an average of less than fifteen minutes. Dr. Lagerwaard discussed the benefits of on-table adaptive treatments in a variety of cancers including pancreas, liver, kidney, lung, and prostate.

“We decided, from the very beginning, to leverage the benefits of MR guidance and MRIdian‘s integrated workflow to perform daily on-table adaptive treatments while using real-time MR tracking for every fraction,” said Dr. Lagerwaard. “With MRI-guidance and the ability to shape the dose on-table, we’re personalizing each treatment to ensure that the highest biologically effective dose is reaching the tumor and nearby healthy tissue and critical organs are spared, in an effort to improve patient outcomes. In our experience, this approach shows great promise, particularly in the treatment of pancreatic cancer.”

At a symposium titled “MRI-Guided RT with MRIdian: Perspectives from Installation to Clinical Use”, more than 400 attendees heard about the clinical experience at the first two European MRIdian centers, Gemelli ART in Rome and VU University Medical Center in Amsterdam, who are using on-table adaptive treatments on a daily basis.
Video highlights of select MRIdian presentations at ESTRO are available on ViewRay’s website at http://www.viewray.com/estro_2017.htm.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.

ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the content and findings of presentations at ESTRO 36, ViewRay’s plans to support a multi-institutional single-arm prospective clinical trial in unresectable pancreatic cancer and references to MRI-guided radiation therapy becoming a new standard of care in cancer treatment. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Contact:
Michael Saracen
Senior Director, Marketing
ViewRay, Inc.
Phone: +1 408-242-2994
Email: media@viewray.com
# # #


Copyright 2017 © ViewRay. All rights reserved   -   Contact ViewRay